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ABSTRACT
Objective: Chronic kidney disease (CKD) is usually diagnosed by measuring the glomerular filtration rate (GFR), and diagnostics are still inadequate 
at the clinical level. Most of the diagnostic kits available estimate GFR rate by determining clearance of serum creatinine using various instrumentation 
generally available at hospitals. Serum creatinine is considered the major marker for renal deficiency disorders. In addition, it is also an indicator of 
muscle mass and dietary intake. Hence, the need for a more reliable marker for CKD arises. A low molecular weight protein cystatin C has been found 
to be a reliable biomarker for the detection of kidney function as it is solely filtered by the glomerulus and not secreted by renal tubules.
Methods: The basic setup of the kit was designed using a syringe containing multiwalled carbon nanotube (MWCNT) conjugated protease. Casein 
beads were immersed in phosphate-buffered saline in the syringe. The glass/MWCNT/papain solid support was subsequently inserted into the 
syringe in such a way that the beads came in contact with the immobilized enzyme conjugate. The inhibitory action of cystatin C against protease 
forms the basis for the functioning of the kit.
Results: Results indicated that papain while immobilization needs to be in dynamic conformation. At 37°C, papain gave better activity as compared 
to protein immobilized at 4°C. Fourier transformation infrared spectroscopy observations confirmed the physical adsorption on the MWCNTs. The 
experimentation confirmed the feasibility of using prototype for detection of cystatin C.
Conclusion: The proposed alternate method may offer a cost effective solution to detection of CKD and its progression. Papain conjugated with 
MWCNT indicated its temperature and pH stability. The initial design of the diagnostic kit for the detection of CKD has shown to be successful with a 
good detection range corresponding to Stages I and II of CKD. Further testing needs to be done for the prototype using patient samples
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INTRODUCTION
Chronic kidney disease (CKD) is the fourth most common kidney disease 
behind kidney infection, kidney stone, and kidney cancer [1]. CKD along 
with acute kidney injury (AKI) is the two broad classifications of renal 
insufficiency, where CKD is characterized by the gradual loss of kidney 
function in contrast to AKI characterized by the sudden loss of kidney 
function [2]. This worldwide public health issue is estimated to affect 
1 in every 10 adults in India, while it is estimated that about 11.6% of 
adults in the US have CKD with similar figures being reported in other 
countries as well [3,4].
It is estimated that CKD-related deaths were pinned at 5.21 million 
in 2008 and is expected to rise to 7.63 million by 2020 [5]. Diabetes 
and high blood pressure are the two most common causes of CKD 
where diabetes accounts for 35% of all cases, while high blood pressure 
accounts for 30% of all CKD cases among other factors such as kidney 
stones, systemic lupus erythematosus, and polycystic kidney disease [6]. 
CKD is divided into five stages based on the severity of the disease, and 
the division is determined by the calculation of glomerular filtration 
rate (GFR). Based on the current available techniques, detection at 
early stage is limited to laboratory-based techniques, and hence, many 
cases are clinically unrecognized. Detection at early levels may provide 
candidates with preventive measures and enable control at early stages.
Over the years, many biomarkers such as creatinine, beta-trace 
proteinuric acid, and cystatin C have been discovered for the detection 
of CKD [7]. Creatinine, considered as a major biomarker, is also an 
indicator of loss in muscle mass, diet, race, and age. It also presents 
a blind spot, i.e., the kidney function has to stop functioning by 50% 
if it needs to be detected, thus posing a serious threat. Hence, there 
is a need for a more suitable marker, which would facilitate detection 
at earlier stages of CKD, thus preventing the severity of the disease to 
arise [8].
Cystatin C, a 13 kDa cysteine protease inhibitor (PI), has been found 
to be solely filtered by renal tubules, and tubular malfunctioning 
will result in increase in urine cystatin C concentration (Fig. 1). The 
concentration of serum cystatin remains fairly constant irrespective of 
age and it lacks the “blind spot,” thus making it a better biomarker than 
creatinine [9,10].
There is a growing body of evidence that suggests that cystatin C 
can be used to detect kidney disease at earlier stages than serum 
creatinine [11], which may help facilitate prevention efforts in the 
elderly and those with diabetes, hypertension, or cardiovascular 
disease Till now, all the assays which have been developed for CKD 
require a hospital- and/or laboratory-based diagnosis (risk, injury, 
failure, loss of kidney function, and end-stage kidney disease analysis, 
GFR monitoring) for confirmation [12].
In this study, a novel diagnostic kit is being proposed for the detection 
of CKD based on the principle of interaction between cystatin C and 
protease. A prototype uses two inhibitors against cysteine protease 
family, namely, cystatin C and antipain hydrochloride. The efficiency 
of the kit was tested using these inhibitors with enzyme conjugate 
multiwalled carbon nanotube (MWCNT) immobilized on a glass slide 
and casein beads used as substrate.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.17001
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MATERIALS AND METHODS
Materials
MWCNT, papain, 3-aminopropyltriethoxysilane (APTES), glutaraldehyde, 
cystatin C, and antipain dihydrochloride were procured from 
Sigma-Aldrich (India). Bradford reagent, sodium chloride, albumin, 
sodium carbonate, Folin-Ciocalteu reagent, tyrosine, 3% trichloroacetic 
acid (TCA), sulfuric acid, and hydrogen peroxide were prepared according 
to the requirements.
Setup of solid support: Immobilization of glass/MWCNT/papain
Microscope glass slide (Axiva Sichem Biotech, New Delhi) was taken 
and cut into small rectangular shape of sizes (1 cm × 2 cm). The slides 
were washed with ethanol and immersed in a Petri plate filled with 
piranha solution (3:1 solution of H2SO4 and H2O2) and incubated at 
70°C for 1 hr. The slides were rinsed with water and dipped in 10% 
APTES and incubated overnight at room temperature (RT). The slides 
were dried. MWCNT was suspended in 10 ml phosphate-buffered 
saline (PBS) solution and activated slides were incubated in the 
suspension with constant agitation. Each glass piece was immersed in 
5 ml (3 mg/ml) of papain solution for 5 hrs with constant agitation and 
stored at 4°C [13].
Selection of substrate and enzyme
Casein beads
500 ml milk was boiled in a beaker and 500 µl-1 ml of acetic acid was 
added. The precipitate was molded into beads (0.5 cm in diameter). 
Beads were dried and stored at RT [14].
Protease activity assay
The protease activity of papain was determined using casein according 
to Ding et al., 2003. Briefly, required amount of free and immobilized 
papain was taken and incubated with phosphate buffer solution (5 ml, 
pH 7) and casein solution (1 ml, 0.5%) at 37°C for 30 minutes. TCA 
(300 µl, 3%) was added as a stopping reagent. Folin-Ciocalteu reagent 
was added and absorbance measured at 670 nm. One unit of enzyme 
activity is defined as 1 µg of tyrosine formed per minute at 37°C [15].
Kinetic study of free and immobilized enzyme
The effect of pH and temperature on the activity of the free and 
immobilized papain was evaluated. Papain activity after was measured 
over a range of pH 5-9. This was followed by monitoring the enzyme 
activity of papain in phosphate buffer solution (3 mg/ml, pH 7.5); solution 
was studied at varying temperature (30-90°C). Thus, the optimum pH 
and temperature for optimal enzyme activity was determined.
Actions of inhibitors of free and immobilized enzymes
The action of cysteine PIs on papain was evaluated. Cysteine PIs such 
as antipain hydrochloride (0.00005-0.008 mg/ml) and cystatin C 
(0.00005-0.008 mg/ml) were tested against free and immobilized 
protease.
Kit preparation
The basic set up of the kit was designed using a syringe. Casein beads 
were immersed in 2ml of PBS in the syringe. The glass/MWCNT/papain 
solid support was subsequently inserted into the syringe in such a way 
that the beads came in contact with the immobilized enzyme conjugate. 
The setup was incubated for 30 minutes at RT, and the elute was tested 
for protease activity at 670 nm. The same procedure was repeated in 
the presence of PIs (Fig. 2)
RESULTS
The measurement of cystatin C (Fig. 3) is based on the concept that 
when an individual suffers from initial stages of CKD, the filtration by 
the glomerulus is affected and cystatin C level rises in the urine. The 
amount of cystatin C in the urine will directly affect the protease which 
is immobilized on the solid support. Thus, the variation in the cystatin C 
will decide the amount of product catalyzed by papain, and hence, 
levels can be colorimetrically quantified. This difference in range was 
assumed to be able to be detected by the kit so that we can categorize if 
an individual is suffering from CKD or not.
Standardization of substrate
Albumin and casein are the most common substrate used for proteases. 
It was found that the reactivity of casein with papain gave better 
results as compared to albumin, hence our selection of substrate. As 
reusability and retrievability of substrate were important factors in kit 
development, casein beads were decided to be used. A slight decrease 
in enzymatic activity between the free and beaded casein was observed 
because of availability of surface of casein beads.
Preparation and standardization of the immobilized papain
Immobilization of papain was carried to facilitate reusability of 
the enzyme. Immobilization of enzyme by physical adsorption was 
preferred over other methods. Immobilization of enzymes at 4°C 
was tested because it was at this temperature the enzyme solution 
remains inactive and stable in storage. Earlier studies indicated papain 
immobilization on metal chelating sepharose being carried out at RT, 
while that on macroporous polymer carrier, temperatures range from 
Fig. 1: Conditional indicators for the presence and absence of 
cystatin C, a protein marker present in urine in symptomatic 
kidney malfunction. In case of normal kidney, no cystatin C will 
be present in the urine although primary disorders may lead to 
increased levels in the plasma
Fig. 2: Diagrammatic summary of setup of glass/multiwalled carbon nanotube (MWCNT)/papain. Template treated with piranha solution 
and 10% 3-aminopropyltriethoxysilane. Slides loaded with MWCNT suspended in phosphate-buffered saline solution for 24 hrs with 
constant agitation. Papain physically adsorbed on MWCNT glass pieces
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0°C to 5°C [16]. However, immobilization of papain at 4°C gave less 
enzyme activity than enzyme immobilized at 37°C. The finding may 
be supported by the fact that for enzymes to immobilize, the protein 
needs to be in dynamic conformation. In addition, it was observed that 
stability of enzyme increased at RT upon immobilization (Fig. 4a).
In a healthy individual, the pH of urine is between 6.0 and 7.0, while 
for patients suffering from CKD, the pH of urine is between 5.0 and 5.5 
depending on the severity of the disease [17]. Thus, it was necessary to 
assess the prototype for its functionality for a variable pH range. Hence, 
the next step was the characterization studies of the enzyme where 
the effect of medium pH on the enzymatic activity of the immobilized 
and free papain was evaluated. The optimal pH of the free enzyme 
solution and immobilized enzyme was 7.5. There was a lack in the 
shift of optimum pH between free and immobilized papain, which 
were normally noticed in other experiments [15]. Considering the 
symptomatic pH for CKD (pH 5-5.5), the immobilized papain indicated 
a comparatively better activity (Fig. 4b).
In the case of MWCNT-papain, the effect of physical adsorption of 
papain on MWCNT was evaluated and immobilization process was 
successful with good enzymatic activity. The relative activity was 
found to be 75% as compared to free enzyme. Fourier transformation 
infrared (FTIR) was used to compare the bonding pattern between the 
MWCNT and MWCNT immobilized with papain. Both MWCNT-NH2 and 
papain immobilized onto MWCNT-NH2 have comparable characteristic 
peaks. A distinct peak could be observed at 1734/cm, indicating the 
presence of ester bonds (Fig. 5). The amide bond represented by –C–N 
(~1400/cm), –N–H amide stretch (3700-3500/cm), and C=O amide 
stretch (1690-1630/cm) [18] was not present in the spectra, and hence, 
it was hypothesized that the enzyme was physically adsorbed on the 
MWCNTs.
Testing of prototype with PIs
As a prototype is being designed, the probability of the functionality 
needed to be tested. Hence, we selected inhibitors antipain 
hydrochloride and cystatin C for the experiment.
Antipain, a peptide isolated from actinomycetes, has also shown specific 
activity toward papain. An in silico study exhibited three structural 
motifs present in cystatins, namely, glycine residue at the N-terminus, 
QxVxG motif situated in the β-hairpin loop, and an aromatic residue on 
the β-hairpin loop enabled binding to active site residues of papain, 
namely, C25, H159, and N175 [19].
The next step was to identify the specificity and sensitivity of the diagnostic 
kit. Cystatin C levels found in the urine ranged from about 0.000052 to 
0.0003 mg/ml in healthy individuals and 0.0005 to 0.0021mg/ml for 
CKD patients [16]. For AKI, the level of cystatin C ranged from 0.0026 to 
0.005 mg/ml, while for kidney tubular dysfunction, the range of cystatin 
C level is much broader from 0.00046 to 0.008 mg/ml [17].
For our test, the inhibitor concentrations were varied from 0.00005 
to 0.008 mg/ml. The relative activity for immobilized papain was 
monitored in the presence of inhibitors. The enzymatic activity in the 
absence of inhibitors (0 mg/ml) was considered to be 100%. The Stage I 
of CKD is characterized by cystatin C level of 0.8 mg/L. The prototype was 
tested at a concentration of 0.00005 mg/ml of antipain hydrochloride; 
the residual activity was found to be 97%. At the same concentration 
of cystatin C, the relative enzymatic activity was 75.3%, which was 
expected as antipain HCl is less specific for papain than cystatin C. 
Similarly, at concentration 0.0005 mg/ml cystatin C (corresponding to 
Stage II CKD), the residual activity (for immobilized papain) was 53%, 
while that for 0.003 mg/ml, the residual activity was about 19% (Fig. 6). 
Thus, from the observations, it can be interpreted that a 20% inhibition 
in activity of the enzyme immobilized, under given set of conditions, can 
be direct indication of Stage I CKD and 50% inhibition indicating Stage II 
CKD. The change of enzyme activity was easily monitored on the basis of 
tyrosine equivalents released and subsequent color changes observed.
A further increase in the concentration above 0.008 mg/ml of inhibitors, 
the enzymatic activity, was found to almost fully inhibit as no detection 
was possible. The experimentation confirmed the feasibility of using 
prototype for detection of cystatin C.
DISCUSSION
A comparison of the available cystatin C (Siemens, Roche, and Genzyme) 
assays available in the market is represented in Table 1 [20,21]. The 
available assays are immunoassay based methods of detection using 
invasive sample for testing. Presently available kits use antibody based 
detection, hence are comparatively costly. Moreover, the range of 
detection is much higher between 0.5 and 5 mg/ml. This high range 
would mean better specificity and accuracy for cystatin C detection.
Progression of CKD with combination drugs has indicated control at 
later stages, but identification at stage I and II may facilitate efficient 
treatment [ 22,23].
Fig. 3: Schematic representation of basic concept of kit. In normal 
kidney, cystatin C is filtered by the glomerulus as a result not 
secreted into the urine, thereby producing a positive result for 
protease activity due to the absence of cystatin C, a cysteine 
protease inhibitor (PI), while in patients suffering from chronic 
kidney disease, cystatin C leaks out the urine giving a negative 
result for protease activity due to the absence of PI (cystatin C)
Fig. 4: (a) Shelf stability of free and immobilized enzyme during storage at room temperature, (b) effect of pH on free and immobilized 
enzyme. The immobilized enzyme has higher functionality at pH 5-5.5 as compared to free enzyme
a b
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CONCLUSION
CKD is usually diagnosed by measuring the rate at which glomeruli 
filter impurities in the blood, also known as GFR. Most of the diagnostic 
kits available estimate GFR rate by determining serum creatinine, 
which is an endogenous substance in the blood that is cleared by the 
kidney. However, it has been reported that few PIs are also released 
in the urine during CKD. For example, low molecular weight protein 
cystatin C is more reliable biomarker for detection of kidney function. 
Keeping these advantages, a novel versatile prototype diagnostic kit was 
designed for the detection of CKD based on the principle of interaction 
between PI (cystatin C) and protease. The prototype thus designed 
utilizes immobilized papain conjugated with MWCNT, indicates its 
temperature and pH stability. The initial design of the diagnostic kit for 
the detection of CKD has shown to be successful with a good detection 
range corresponding to Stages I and II of CKD. Further testing needs to 
be done for the prototype using patient samples.
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